Check your medication information with the MKSAP problem, in partnership with the American School of Physicians.

A 58-year-old man is evaluated in follow-up for idiopathic pulmonary fibrosis (IPF), which was identified 2 years in the past. He has cough and shortness of breath and now requires supplemental oxygen at relaxation. Earlier evaluations haven’t recognized any trigger for his signs apart from progressive IPF. He has participated in pulmonary rehabilitation and continues in a upkeep program. He’s a lifelong nonsmoker. His medical historical past is in any other case unremarkable, and he takes no medicines.

On bodily examination, the affected person is afebrile, blood strain is regular, pulse price is 96/min, and respiration price is 26/min; BMI is 27. Oxygen saturation is 92% respiration four L of oxygen by nasal cannula. Pulmonary examination reveals inspiratory crackles on the bases bilaterally.

Outcomes of a 6-minute stroll take a look at are 335 meters (1100 ft) (declined from 457 meters [1500 feet] 6 months in the past).

Which of the next is essentially the most applicable administration?

A. Azathioprine
B. Each day prednisone
C. Etanercept
D. Lung transplantation

MKSAP Reply and Critique

The proper reply is D: Lung transplantation.

Probably the most applicable administration is referral to a lung transplantation program. People thought-about for lung transplantation are most frequently at excessive danger of dying inside 2 years as a consequence of respiratory failure and still have a excessive probability of long-term survival following the process. This affected person with idiopathic pulmonary fibrosis (IPF) has a big oxygen requirement at relaxation along with a documented decline in his 6-minute stroll distance. Each of those components considerably enhance his danger for the event of respiratory failure. Moreover, he has no historical past of comorbidities that will restrict posttransplant survival, and he continues to actively take part in pulmonary rehabilitation. Lung transplantation stays the one intervention with a transparent survival profit for choose sufferers with IPF.

Medical choices for remedy of IPF are restricted. The immunosuppressant azathioprine, given together with prednisone and N-acetylcysteine, has been studied in sufferers with IPF. Nevertheless, this mixture remedy was related to elevated mortality and adversarial results.

Due to this fact, azathioprine isn’t really helpful to be used in sufferers with IPF. In associated research, N-acetylcysteine used as single-agent remedy in IPF confirmed no profit over placebo; thus, N-acetylcysteine can be now not thought-about of worth for remedy of IPF.

Though there may be some debate as to the good thing about glucocorticoids within the remedy of sufferers with an acute exacerbation of IPF, there is no such thing as a profit to both short- or long-course prednisone in sufferers with IPF with out an exacerbation. IPF is a illness with ongoing fibrosis however with restricted irritation. Consequently, glucocorticoids do little to have an effect on the progressive fibrosis, and their many related unwanted side effects solely place the affected person at elevated danger of problems.

Therapy with tumor necrosis factor-α (TNF-α) inhibitors has been proposed as a way for lowering the progressive pulmonary fibrosis related to IPF. Nevertheless, a trial of the TNF-α inhibitor etanercept failed to indicate profit, and its use isn’t really helpful in IPF.

Two new medical therapies have lately been authorised for remedy of IPF. These are nintedanib, a tyrosine kinase inhibitor that moderates manufacturing of fibrogenic progress components, and pirfenidone, whose mechanism is unclear but in addition modulates manufacturing of fibrosis. Each brokers gradual the decline in pulmonary perform exams however don’t have an effect on high quality of life and usually are not healing. The impact of those brokers on illness development seems to be very related. To this point, these brokers haven’t been studied extensively in sufferers with acute exacerbation of IPF or severely superior IPF. Pulmonary subspecialty evaluation to verify IPF and assess danger/profit for using these medicine in chosen sufferers is really helpful. Consideration of participation in scientific trials for sufferers with this progressive dysfunction stays vital for the event of future, more practical, medical therapies.

Key Level

  • Sufferers with idiopathic pulmonary fibrosis who’ve a excessive danger for the event of respiratory failure and a excessive probability of long-term posttransplant survival ought to be referred to a lung transplantation program, and about treating the “apprehensive nicely.”

This content material is excerpted from MKSAP 17 with permission from the American School of Physicians (ACP). Use is restricted in the identical method as that outlined within the MKSAP 16 Digital license settlement. This materials ought to by no means be used as an alternative choice to scientific judgment and doesn’t signify an official place of ACP. All content material is licensed to KevinMD.com on an “AS IS” foundation with none guarantee of any nature. The writer, ACP, shall not be answerable for any injury or lack of any form arising out of or ensuing from use of content material, no matter whether or not such legal responsibility is predicated in tort, contract or in any other case.




Supply hyperlink